Cancer Research Landon Prizes for Basic and Translational Cancer Research  Tumor Immunology: New Perspectives
HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online

[Cancer Research 26, 1349-1360, July 1, 1966]
© 1966 American Association for Cancer Research

This Article
Right arrow Full Text (PDF)
Right arrow Alert me when this article is cited
Right arrow Alert me if a correction is posted
Services
Right arrow Similar articles in this journal
Right arrow Similar articles in PubMed
Right arrow Alert me to new issues of the journal
Right arrow Download to citation manager
Right arrow reprints & permissions
Citing Articles
Right arrow Citing Articles via Google Scholar
Google Scholar
Right arrow Articles by Flamm, W. G.
Right arrow Articles by Counts, W. B.
Right arrow Search for Related Content
PubMed
Right arrow PubMed Citation
Right arrow Articles by Flamm, W. G.
Right arrow Articles by Counts, W. B.

Topical Application of Actinomycin D on Mouse Skin: Effect on the Synthesis of Ribonucleic Acid and Protein

W. Gary Flamm, M. R. Banerjee and Wayne B. Counts

Carcinogenesis Studies Branch, National Cancer Institute, Bethesda, Maryland

Topical application of actinomycin D inhibits the synthesis of RNA in mouse skin. The maximum inhibition obtained was approximately 75% and was distributed uniformly throughout the interfollicular and follicular epidermal cells. This inhibition was produced by dosage levels which ranged from 1 µg of actinomycin administered once to 15 µg given 6 times every 3 hr. Regardless of the dosage level used, the layer of cells closest to the surface of skin was always inhibited within a shorter period following the topical application of actinomycin D than were the deeper lying cells. Inhibition required 2–3 days to reach a uniform level throughout the epidermis. The duration of inhibition (5–11 days), however, was dependent upon the dosage level applied. Evidence is presented which shows that topical applications of actinomycin D function only locally and do not alter RNA metabolism in either the untreated areas of skin or systemic organs. Inhibition of RNA synthesis as considered at the molecular level is not random but instead appears to be highly specific for ribosomal RNA. However, the possibility that messenger RNA was also inhibited, but to an immeasurable extent, was not eliminated. Protein synthesis, as measured by the incorporation of leucine-3H into skin protein, was not significantly altered by a low dosage level of actinomycin (1 µg). Application of a high level (15 µg administered 6 times), however, produced an increase in rate of leucine uptake (35% by 4 days). Alterations in the mitotic index of interfollicular cells, as well as hyperplasia, were observed at the higher dosage level.

Received 11/ 5/65.





HOME HELP FEEDBACK SUBSCRIPTIONS ARCHIVE SEARCH TABLE OF CONTENTS
Cancer Research Clinical Cancer Research
Cancer Epidemiology Biomarkers & Prevention Molecular Cancer Therapeutics
Molecular Cancer Research Cancer Prevention Research
Cancer Prevention Journals Portal Cancer Reviews Online
Annual Meeting Education Book Meeting Abstracts Online
Copyright © 1966 by the American Association for Cancer Research.